Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2021-03-05
Original market date: See footnote 1
2021-03-05
Product name:
BIVALIRUDIN INJECTION
Description:
SINGLE USE
DIN:
02505517
Product Monograph/Veterinary Labelling:
Date:
2020-09-24
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
AVIR PHARMA INC.
660 Boulevard Industriel
Blainville
Quebec
Canada
J7C 3V4
Class:
Human
Dosage form(s):
Solution
Route(s) of administration:
Intravenous
Number of active ingredient(s):
1
Schedule(s):
Prescription
American Hospital Formulary Service (AHFS): See footnote 3
20:12.04.12
Anatomical Therapeutic Chemical (ATC): See footnote 4
B01AE06 BIVALIRUDIN
Active ingredient group (AIG) number:See footnote5
0148342002
| Active ingredient(s) | Strength |
|---|---|
| BIVALIRUDIN | 5 MG / ML |